Jupiter Topco LLC Takes $170.51 Million Position in Crinetics Pharmaceuticals, Inc. $CRNX

Posted by Brenda Bartman on Aug 27th, 2026

Jupiter Topco LLC bought a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) during the 2nd quarter, Holdings Channel reports. The fund bought 4,557,689 shares of the company’s stock, valued at approximately $170,509,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its position in shares of Crinetics Pharmaceuticals by 107.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 639 shares of the company’s stock worth $30,000 after purchasing an additional 331 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of Crinetics Pharmaceuticals in the 2nd quarter worth $30,000. Raymond James Financial Inc. acquired a new position in shares of Crinetics Pharmaceuticals during the second quarter valued at about $45,000. Parallel Advisors LLC grew its position in Crinetics Pharmaceuticals by 34.6% during the 4th quarter. Parallel Advisors LLC now owns 1,225 shares of the company’s stock worth $57,000 after purchasing an additional 315 shares during the last quarter. Finally, Arax Advisory Partners increased its stake in Crinetics Pharmaceuticals by 131.2% during the 4th quarter. Arax Advisory Partners now owns 1,498 shares of the company’s stock valued at $70,000 after purchasing an additional 850 shares in the last quarter. 98.51% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Crinetics Pharmaceuticals

In other Crinetics Pharmaceuticals news, Director Stephanie Okey sold 6,900 shares of Crinetics Pharmaceuticals stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $35.67, for a total transaction of $246,123.00. Following the completion of the transaction, the director owned 6,400 shares in the company, valued at approximately $228,288. This trade represents a 51.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Coelho Rogerio Vivaldi sold 3,000 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $40.00, for a total value of $120,000.00. Following the completion of the transaction, the director directly owned 19,225 shares of the company’s stock, valued at approximately $769,000. This trade represents a 13.50% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.80% of the company’s stock.

Crinetics Pharmaceuticals Price Performance

NASDAQ:CRNX opened at $84.84 on Thursday. The firm has a market capitalization of $9.00 billion, a P/E ratio of -16.83 and a beta of 0.12. Crinetics Pharmaceuticals, Inc. has a 1-year low of $30.24 and a 1-year high of $84.88. The company’s fifty day moving average price is $72.02 and its 200-day moving average price is $50.21.

Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) last issued its earnings results on Monday, August 3rd. The company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.18) by $0.04. Crinetics Pharmaceuticals had a negative net margin of 1,189.88% and a negative return on equity of 44.22%. The firm had revenue of $25.12 million during the quarter, compared to analysts’ expectations of $14.84 million. During the same quarter last year, the company posted ($1.23) earnings per share. The firm’s revenue was up 2336.9% compared to the same quarter last year. Equities analysts anticipate that Crinetics Pharmaceuticals, Inc. will post -4.83 EPS for the current fiscal year.

Analysts Set New Price Targets

CRNX has been the subject of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Crinetics Pharmaceuticals in a research note on Friday, July 17th. Piper Sandler downgraded Crinetics Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Oppenheimer reissued a “market perform” rating on shares of Crinetics Pharmaceuticals in a report on Tuesday, July 7th. UBS Group restated a “neutral” rating and issued a $85.00 price objective (up from $55.00) on shares of Crinetics Pharmaceuticals in a research note on Tuesday, July 28th. Finally, Wall Street Zen raised Crinetics Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. Five analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Crinetics Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $81.00.

Read Our Latest Research Report on CRNX

About Crinetics Pharmaceuticals

(Free Report)

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.